WEBULL
News
SLP
12.29
+1.49%
0.18
Simulations Plus Extends Research Collaborations with FDA and NIEHS
Reuters · 3d ago
Simulations Plus announces extensions of FDA and NIEHS research collaborations
TipRanks · 4d ago
Simulations Plus verlängert Forschungskooperationen mit FDA und NIEHS
Reuters · 4d ago
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
Barchart · 4d ago
Weekly Report: what happened at SLP last week (0202-0206)?
Weekly Report · 5d ago
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simply Wall St · 6d ago
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Simply Wall St · 02/06 15:46
Simulations Plus CEO to Participate in Major Investor Conferences
Reuters · 02/05 17:35
Simulations Plus nimmt an mehreren bedeutenden Investorenkonferenzen teil
Reuters · 02/05 17:35
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
PR Newswire · 02/03 22:30
Simulations Plus CEO to Join Key Healthcare Investor Conferences
Reuters · 02/03 21:06
Simulations Plus nimmt an mehreren internationalen Investorenkonferenzen teil
Reuters · 02/03 21:06
Weekly Report: what happened at SLP last week (0126-0130)?
Weekly Report · 02/02 09:46
Weekly Report: what happened at SLP last week (0119-0123)?
Weekly Report · 01/26 09:46
Iridium NTN Direct Sets for Beta Entry After Successful Testing
NASDAQ · 01/22 17:31
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Simulations Plus (SLP)
TipRanks · 01/22 14:50
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Karyopharm Therapeutics (KPTI) and Simulations Plus (SLP)
TipRanks · 01/22 12:21
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Simulations Plus (SLP), DENTSPLY SIRONA (XRAY) and HCA Healthcare (HCA)
TipRanks · 01/22 11:40
Simulations Plus Unveils AI-Enabled Drug Development Platform at 2026 Investor Day
Reuters · 01/21 21:06
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.